MiMedx to Acquire Sanara MedTech for $350M, Projects Combined Revenue Over $400M in 2027
MDXG sits 37% above its 52-week low of $3.025.
Summary
MiMedx Group will acquire Sanara MedTech for $350M in cash and stock, combining two surgical-focused regenerative medicine companies. The deal is expected to nearly double surgical revenue, with combined 2027 revenue projected above $400M and Adjusted EBITDA margins exceeding 20%.
Key Events · M&A and Partnerships · MDXG
-
Acquisition of Sanara MedTech
MiMedx will acquire all outstanding shares of Sanara for $33.00 cash and 0.4735 MiMedx shares per Sanara share, valuing Sanara at $35 per share and a total enterprise value of approximately $350 million.
-
Combined Financial Projections
Post-close, combined 2027 total revenue is expected to be well in excess of $400 million with an Adjusted EBITDA margin above 20%, including over $20 million in annual run-rate cost synergies.
-
Financing Details
The cash portion will be funded with a $300 million Senior Secured Term Loan from Hayfin Capital Management (6-year, SOFR + 6.25%) and cash on hand. MiMedx will issue approximately 4.4 million shares for the stock consideration.
-
Strategic Rationale
The combination nearly doubles MiMedx's surgical revenue, expands its product portfolio into collagen particulate, surgical irrigation, and bone fixation, and adds significant commercial scale through Sanara's 450+ contracted distributors and 1,450+ active facilities.
Analysis · MDXG · Industrial Applications And Services
A definitive agreement will see MiMedx Group acquire Sanara MedTech for approximately $350 million in cash and stock. The deal nearly doubles MiMedx's surgical revenue, adds a portfolio of regenerative surgical products, and is expected to be immediately accretive to revenue growth and margins. According to the investor presentation, combined 2027 revenue is projected to exceed $400 million with an Adjusted EBITDA margin above 20%, driven by over $20 million in run-rate cost synergies. Financing includes a $300 million term loan at SOFR + 6.25% and issuance of 4.4 million MiMedx shares. The transaction transforms MiMedx into a leading surgical regenerative medicine company with a significantly expanded addressable market.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDXG was trading at $4.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $630M. The 52-week trading range was $3.03 to $7.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.